# Quick Replies — r/genomics AlphaGenome Post

**Purpose:** Copy-paste ready answers для быстрых ответов (first 2h critical for engagement)

---

## Q1: "Why only 6 loci?"

**Answer:**
```
Proof-of-concept for mechanism specificity framework. We're expanding to 10-20 loci next (seeking collaborators). Small N per locus (15-50 variants) limits statistical power, but 6/6 consistency suggests robust pattern — regulatory loci show concordance, coding loci show orthogonality as expected if AlphaGenome captures regulatory mechanisms distinct from protein-level effects.
```

---

## Q2: "Where's the code/data?"

**Answer:**
```
Analysis code available on request (Python scripts, reproducible pipeline). Email: sergeikuch80@gmail.com

Data sources:
- ClinVar VCV IDs (public): see ADR-027 to ADR-030 in our documentation
- AlphaGenome predictions: public API at https://alphagenome.ai
- ARCHCODE SSIM scores: available on request
- Variant lists: all ClinVar P/LP and B/LB, category-matched by functional consequence

Happy to share everything for replication.
```

---

## Q3: "Is ARCHCODE validated?"

**Answer:**
```
ARCHCODE is our in-house 3D chromatin disruption model (SSIM-based loop stability). Not yet published, but this validation tests RELATIVE correlation (AlphaGenome vs ARCHCODE), not absolute performance. 

Even if ARCHCODE is imperfect, the mechanism specificity finding is robust: coding loci show null correlation between the two methods (ρ=-0.12 to 0.08), exactly as expected if they measure orthogonal mechanisms (regulatory vs protein-level).

We're transparent about this — it's testing whether AlphaGenome captures something distinct, not whether ARCHCODE is perfect.
```

---

## Q4: "Can I replicate this?"

**Answer:**
```
Yes! All data sources are public or available on request:

1. ClinVar variants: Use VCV IDs from our documentation (ADR-027 to ADR-030)
2. AlphaGenome predictions: Public API at https://alphagenome.ai
3. Hi-C data: ENCODE (we used K562 for most loci)
4. ARCHCODE SSIM scores: Email me (sergeikuch80@gmail.com) and I'll send

Analysis pipeline: Python scripts with pandas, scipy, matplotlib. Happy to share reproducible code.
```

---

## Q5: "What about wet-lab validation?"

**Answer:**
```
We're computational-only. Seeking wet-lab collaborators to test TERT hotspot CAGE predictions experimentally:

- C228T: AlphaGenome predicts +33.7% CAGE increase (gain-of-function)
- C250T: AlphaGenome predicts +53.1% CAGE increase

These are known cancer hotspots that create de novo ETS binding sites. Would be great to validate CAGE-seq experimentally in cell lines with/without these mutations.

If you're interested or know someone who is — please reach out!
```

---

## Q6: "Small N — how reliable?"

**Answer:**
```
You're right to flag this. Acknowledged in our Limitations section:

1. Small N per locus (15-50 variants) limits statistical power
2. Category-selection bias (we selected by functional consequence, not by ARCHCODE scores) may inflate some correlations
3. Tissue mismatch (FANTOM5 CAGE vs blood chromatin for ARCHCODE) may explain WEAK-ORTHOGONAL results

BUT: 6/6 loci consistency (all regulatory show concordance/weak-orthogonal, all coding show orthogonal) suggests the pattern is robust despite small N. We're not claiming high predictive accuracy — we're testing mechanism specificity (do these methods measure different things?), which needs fewer samples if effect is strong.

Expanding to 10-20 loci to confirm.
```

---

## Q7: "WEAK-ORTHOGONAL — what does that mean?"

**Answer:**
```
WEAK-ORTHOGONAL = correlation ≈ 0 (orthogonal mechanisms) BUT only one method separates groups on this dataset.

Example: HBB regulatory variants
- AlphaGenome: p=0.00027 (strong separation of P/LP vs B/LB)
- ARCHCODE: p=0.21 (weak separation)
- Spearman ρ=0.069 (≈0, orthogonal)

Interpretation: Both detect regulatory disruption (hence weak positive correlation), but AlphaGenome is stronger on promoter-selected variants (sampling bias in our dataset).

Alternative simpler classification: CONCORDANT if both p<0.05 and ρ>0.3, ORTHOGONAL otherwise. WEAK-ORTHOGONAL is intermediate category. Open to feedback on whether this distinction is useful!
```

---

## Q8: "How is this different from just using CADD?"

**Answer:**
```
CADD is protein-centric (trained mostly on coding variants). AlphaGenome uses CAGE-seq (regulatory activity), ARCHCODE uses 3D chromatin structure (loop stability).

Key difference: regulatory variants often have low CADD scores but high AlphaGenome/ARCHCODE scores. Example from our HBB analysis — many "pearls" (structural pathogenic variants) have CADD <20 but strong CAGE signal disruption.

They complement each other: CADD for coding, AlphaGenome/ARCHCODE for regulatory.
```

---

## Q9: "Why tissue mismatch (FANTOM5 vs blood)?"

**Answer:**
```
Good catch. AlphaGenome uses FANTOM5 CAGE data (diverse tissues, population-level), ARCHCODE uses K562 Hi-C (erythroid cell line). This is a limitation we acknowledge explicitly.

Tissue mismatch likely explains why some loci show WEAK-ORTHOGONAL instead of full CONCORDANT — both methods detect regulatory disruption, but tissue-specific effects reduce correlation.

Ideally: tissue-matched CAGE + Hi-C for the same locus. But FANTOM5 is population-scale, K562 is best available for HBB/MLH1. Future work: match tissues more carefully.
```

---

## Q10: "This sounds like validation theater"

**Answer:**
```
Fair concern — we're vigilant about this. Here's how we avoid it:

1. **Honest limitations section**: Explicitly state small N, tissue mismatch, category-selection bias, no variant-level predictions yet
2. **Forensic audit**: 5/5 layers PASS (ClinVar source, genomic coordinates, AlphaGenome API, statistical calculations, TERT biology)
3. **No overclaim**: We say "pilot validation" and "mechanism specificity" not "clinical-ready predictor"
4. **Caught our own mistakes**: Initially claimed 7 loci, corrected to 6 before publication (removed phantom LDLR/CFTR data)
5. **Data available**: All ClinVar IDs, AlphaGenome API public, ARCHCODE scores on request

If you see specific red flags — please call them out! We want this to be honest validation, not theater.
```

---

## Negative Comment Response Template

**If criticism is valid:**
```
You're right — [acknowledge the specific point]. We [mentioned this in Limitations / should have been clearer about this]. 

[Explain what we'll do differently next time or why this doesn't invalidate the main finding]

Thanks for the feedback — this will improve our methods note.
```

**If criticism is misunderstanding:**
```
I think there's a misunderstanding here. [Clarify without being defensive]

[Provide specific evidence from the post or data]

Does that address your concern? Happy to discuss further.
```

**If criticism is unfair/aggressive:**
```
I appreciate the skepticism — it's important for scientific rigor. 

[Address the factual part calmly, ignore the tone]

[Offer to discuss offline if needed]: If you'd like to dive deeper, happy to email (sergeikuch80@gmail.com) or hop on a call.
```

---

## Collaborator Interest Response

**If wet-lab interest:**
```
That's fantastic! We're especially interested in TERT hotspot validation (C228T/C250T gain-of-function CAGE predictions).

Here's what we can provide:
- Variant coordinates (hg38)
- AlphaGenome CAGE predictions (reference vs mutant)
- ARCHCODE structural predictions
- Analysis pipeline for integration with your data

Email me at sergeikuch80@gmail.com and let's discuss a collaboration.
```

**If computational collaborator:**
```
Great! We're expanding to 10-20 loci and could use help with:
- Cross-locus validation framework
- Tissue-matched CAGE + Hi-C integration
- Variant-level predictions (beyond group-level)

Are you interested in co-authorship on a methods note? Email: sergeikuch80@gmail.com
```

**If Weisburd lab/AlphaGenome authors:**
```
Honored to have your attention! We designed this validation to be independent but would love your feedback on methodology.

Specific questions for you:
1. Do you see bifurcation-like behavior in CAGE-seq when CTCF sites are disrupted?
2. Are there known cases where AlphaGenome CAGE signal increases (gain-of-function) like we saw in TERT hotspots?
3. Would you be interested in collaborating on cross-locus expansion?

Email: sergeikuch80@gmail.com or happy to discuss here.
```

---

## Author Question Response

**If tagged with "OP":**
```
OP here — [answer the question]

[If relevant, link to specific part of post or documentation]

Let me know if that answers your question or if you'd like more detail!
```

---

**Usage:**
1. Copy entire answer block (including formatting)
2. Paste into Reddit comment box
3. Read once to check context-appropriate
4. Post
5. Log in `forum_post_feedback.md`

**Tone guidelines:**
- Professional but friendly (not academic-stiff)
- Acknowledge limitations honestly
- Offer data/code immediately when asked
- Thank people for good questions
- Don't defend aggressively — curiosity > ego

---

**Last updated:** 2026-05-14
